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Abstract
Objective—To examine the use of medical management, uterus-preserving surgery (UPS), and 
complementary treatments among women with uterine fibroids.
Study design—Prospective cohort study of 933 premenopausal women ages 31-54 years with 
symptomatic fibroids who participated in the Study of Pelvic Problems, Hysterectomy, and 
Intervention Alternatives (SOPHIA) for an average of 4.3 years (SD 2.5 years). Incident use of 
fibroid treatments was determined through annual interviews. Linear regression models were used 
to compare changes in fibroid-related symptoms among women who underwent UPS versus those 
who did not undergo surgery.
Results—Participants were racially and ethnically diverse, with a mean age of 43 years. During 
study follow-up, 531 participants (57%) did not undergo UPS or hysterectomy, 250 (27%) had at 
least one UPS, and 152 (16%) underwent hysterectomy. Complementary and alternative 
treatments were commonly used, including exercise (45%), diet (34%), herbs (37%), and 
acupuncture (16%): participants reported significant symptom improvement and few side effects 
with these interventions. In multivariable linear regression models, women who did not undergo 
surgery during the study reported improvement in dyspareunia (p<.001), pelvic pain (p<.001), and 
menstrual cramps (p<.001). However, women who underwent UPS reported greater overall 
resolution of “pelvic problems” compared with women who did not have surgical treatment 
(difference in change score 1.18 on a 4-point Likert scale, p<.001).
Conclusion—UPS are effective treatments for women with fibroids, but many women use 
hormonal or complementary treatments and report significant symptom improvement without 
surgical intervention.
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Introduction
Uterine fibroids occur in approximately 25% of reproductive-age women. Hysterectomy is 
the only definitive treatment, but many women seek uterus-preserving surgeries (UPS) such 
as myomectomy, uterine artery embolization and endometrial ablation, or a trial of medical 
management or complementary and alternative medicine (CAM) [1-5]. Despite the 
prevalence of fibroids and the myriad of available treatments, the current literature is limited 
in scope and quality to fully inform treatment decisions [6]. Several studies have reported 
the rate of an additional UPS or hysterectomy following a first UPS [7-11]. However, the 
likelihood of undergoing a first UPS or a hysterectomy among women with symptomatic 
fibroids is less well described and little is known about the effect of medications or CAM on 
fibroid-related symptoms [12,13].
We present an analysis of the use and effectiveness of UPS and nonsurgical treatments 
among 933 premenopausal women with symptomatic fibroids who were enrolled in the 
Study of Pelvic Problems, Hysterectomy, and Intervention Alternatives (SOPHIA). Our 
results will help guide and inform counseling for women who present with symptomatic 
fibroids, especially those who hope to avoid hysterectomy.
Materials and methods
Details of the SOPHIA methods and measures have been described [14,15]. In brief, 
SOPHIA was a prospective cohort study of premenopausal women, aged 31-54 years, 
presenting to gynecologic clinics in the San Francisco Bay area. For this analysis, all 
SOPHIA participants who self-reported a diagnosis of symptomatic fibroids with abnormal 
uterine bleeding or pelvic pressure at the time of their baseline interview and completed at 
least one follow-up interview were included. Women with a history gynecologic cancer 
were excluded. Participants were enrolled from 1998 to 2004. Institutional review boards at 
all hospital sites approved the study and all women gave informed consent for participation.
SOPHIA participants underwent yearly face-to-face interviews for up to 8 years. The 
questionnaires assessed a broad array of pelvic symptoms associated with fibroids. 
Participants were asked how bothered they were in the last 4 weeks by dyspareunia, pelvic 
pain, pelvic pressure, bladder pain, frequent urination, low back pain, and menstrual cramps. 
Answers to these symptom questions were reported on a 5-point severity scale which ranged 
from “not at all bothered” to “extremely bothered.” We also utilized a global question: “To 
what extent would you say your pelvic problems have been resolved?” Answers were 
reported on a 4-point scale which ranged from “not at all” to “completely.”
Participants were asked about their use of surgical and nonsurgical treatments during the 
annual interviews. Myomectomy, endometrial ablation, or uterine artery embolization were 
classified as a UPS. Nonsurgical treatments were categorized as western medicine 
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(hormonal contraception with estrogen and/or progestin, nonsteroidal analgesics, narcotic 
pain medication) or CAM (exercise, herbs, diet, acupuncture, physical therapy). For all 
western medicines, participants were asked whether they used a treatment specifically for 
bleeding and/or pelvic pain, and not for contraception or other symptoms. For CAM, 
participants were asked whether or not they were using the treatment for “pelvic problems.” 
When a participant reported use of a treatment, two follow-up questions further explored her 
experience with the treatment: (1) “What effect did (the treatment) have on your 
symptoms?” and (2) How bothered were you by side effects of this treatment? For the 
effectiveness question, 5 response options ranging from “made them a lot better” to “made 
them a lot worse” were offered, and for the side effects question, 4 response options ranging 
from from “a lot” to “not at all” were used.
Associations between baseline sociodemographic characteristics and symptoms with the 
most invasive surgical interventions that participants underwent during the study period 
were tested via chi-squares and ANOVAs. Nonsurgical treatment effect is reported as the 
percentage of women using the treatment who stated that treatment made their symptoms “a 
lot better.” Side effects are reported as the percentage of women using the treatment who 
answered that side effects bothered them “a lot” or “some.” We calculated the change in 
symptoms from baseline to the last interview among women who did not undergo surgery 
during the study period and among women who underwent any UPS. We compared the 
difference in change scores between these two groups of participants using linear regression 
in a model that controlled for age, race/ethnicity, educational attainment, year of 
recruitment, length of follow-up period, and entry into menopause. For questions that 
addressed changes in bleeding symptoms, we excluded women who reported the onset of 
menopause during the study period. All analyses were conducted using SAS for Windows, 
version 9.
Results
Among 1,503 SOPHIA participants, this analysis includes the 933 women (62%) who had 
presented for care with symptomatic fibroids in the year prior to study enrollment and 
completed at least one follow-up interview. Participants were followed for an average of 4.2 
years (SD 2.5 years): 9% were lost to follow-up after the baseline interview. Over the course 
of the study period, 531 participants (57%) did not undergo UPS or hysterectomy, 250 
(27%) had at least one UPS, and 152 (16%) underwent hysterectomy with or without an 
antecedent UPS (Table 1). The study cohort was racially and ethnically diverse, with a mean 
age of 43 years. At baseline, study participants reported high rates of fibroid-related 
symptoms including frequent bleeding (66%) and/or pelvic pressure (49%), and 57% 
reported pelvic pain as a result of fibroids (Table 1). There were no statistically significant 
differences in baseline symptoms among women who did not undergo surgery during study 
follow-up compared with women who underwent UPS or hysterectomy.
The majority of participants had not undergone surgery for fibroids prior to enrollment in 
the study (Table 2, n=715, 77% of cohort). Among these women, 74% did not undergo any 
surgery over an average of 3.7 years of follow-up, while 7% had a myomectomy and 15% 
underwent hysterectomy (4.8 years and 5 years of follow-up respectively). Women with a 
Jacoby et al. Page 3
Eur J Obstet Gynecol Reprod Biol. Author manuscript; available in PMC 2015 November 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
history of myomectomy had a reoperation rate of 11% for myomectomy and 19% for 
hysterectomy (6 years and 5.8 years of follow-up respectively).
Western medication was commonly used among women who did not undergo surgery 
during the study period and had no prior history of UPS (Fig. 1). Anti-inflammatory 
analgesics were the most frequently used medication (70%), followed by narcotic pain 
medication (29%). CAM was used by many women to relieve fibroid-related symptoms: 
exercise (40%), herbs (37%), and diet (34%) were the most common. Among participants 
who used hormonal contraception, 55% reported that combined hormonal contraception 
made them a lot better, but 22% were bothered by side effects of these medicines (Fig. 2). 
The progestin intrauterine device (IUD) had the highest proportion of women who reported 
feeling a lot better as a result of its use (71%) and a low rate of bothersome side effects 
(24%). For CAM (Fig. 3), improvement in symptoms was somewhat lower than for 
hormonal medication (exercise 39%, herbs 38%, physical therapy 41%), but bothersome 
side effects were rare (<5% for all therapies).
In the multivariable model, we observed improvements over time in pelvic symptoms 
among women who did not undergo surgery during the study follow-up, as well as among 
those who underwent UPS (Table 3). In a global assessment of whether or not pelvic 
problems had resolved, women who underwent UPS reported greater improvement 
compared with women who did not undergo surgery (difference in change score 1.18, p<.
001). At baseline, scores for this question were not significantly different between groups 
(mean 1.65 for no surgery, 1.33 for UPS). Women who did not undergo a surgical 
intervention reported significant improvements in dyspareunia (change score -1.31, p<.001), 
bladder pain (-0.56, p<.001), and menstrual cramps (-0.39, p<.001). There were no 
statistically significant differences between groups for improvement in the duration or 
quantity of bleeding, pelvic or low back pain, pelvic pressure, or menstrual cramps. Women 
who underwent UPS reported greater improvements in bladder pain (difference in change 
scores equaled -0.67, p=.003), and frequent urination (difference in change scores equaled 
-0.83, p<.001) compared with women who did not have surgery.
Comment
In this diverse cohort of 933 premenopausal women with symptomatic fibroids, we report 
several novel findings for nonsurgical management. At baseline, study participants were a 
symptomatic group with high rates of abnormal bleeding, pelvic pain, or pelvic pressure 
attributed to fibroids. Despite these symptoms, 57% of participants did not undergo any 
surgical intervention throughout the study period. Many of these women utilized hormonal 
contraception and/or analgesics to relieve symptoms and reported that these medications 
significantly improved their symptoms. CAM was also commonly used to relieve fibroid-
related symptoms, and 38-46% reported that these treatments made their symptoms “a lot 
better”. As expected, women who underwent a UPS during the study reported a decrease in 
many bothersome symptoms and an overall improvement in their “pelvic problems”. 
However, we also observed significant improvements over time in “pelvic problems” as well 
as dyspareunia, pelvic pressure, bladder pain, and menstrual cramps among women who did 
not undergo surgery. Surgery provided greater relief compared with no surgery in only a few 
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symptom areas in a multivariable model, although both groups had similar levels of 
symptom severity at baseline.
The change in fibroid symptoms over time in premenopausal women without surgical 
intervention is not well understood. DeWaay et al. reported spontaneous regression and even 
complete resolution of some fibroids among premenopausal women examined with serial 
sonography over 2.5 years [16]. Another longitudinal study found that 7% of fibroids 
decreased in size among 72 premenopausal women evaluated with repeated magnetic 
resonance imaging (MRI) [17]. This natural decrease in fibroid size over time among some 
women may help explain the symptom improvements we observed for women who did not 
undergo surgery. Hormonal therapy, used by many participants who did not undergo 
surgery, may have an effect on fibroid growth. Oral contraceptives and depoprovera have 
been shown to decrease the risk of developing fibroids in some studies [18-20]. The clinical 
improvements among women who did not undergo surgery may therefore reflect the 
effectiveness of hormonal medication, or analgesics, or CAM to decrease fibroid-related 
symptoms by controlling heavy bleeding and pelvic discomfort.
There are few studies that report the proportion of symptomatic women who undergo a first 
surgery to treat fibroids over several years of follow-up. In our cohort, among women with 
no prior surgery at study enrollment, 27% reported a first UPS and 16% had a hysterectomy. 
This is a similar rate of hysterectomy to a cohort of women in North Carolina with fibroids 
≥5 centimeters followed for 1 year (15%), but those women had a higher rate of 
myomectomy (17% vs. 7%) [12]. In a retrospective chart review of 421 women with 
fibroids in Cleveland who had a median follow-up of 29 months, the hysterectomy rate was 
29% [13]. Although the rate of surgery is likely influenced by many factors including fibroid 
size, number and location, symptom severity, and local practice patterns, these prior studies 
combined with our data indicate that the majority of women with symptomatic fibroids are 
successfully managed without surgical intervention.
The likelihood of reoperation following a UPS informs counseling for women considering 
surgery for fibroids. Among women with a prior myomectomy, 11% underwent a repeat 
myomectomy over 6 years of follow-up and 19% underwent hysterectomy over 5.8 years of 
follow-up. These rates are consistent with prior studies that have found 10-25% of women 
require an additional major surgery to treat fibroids after myomectomy [8,9,11]. Women 
with prior uterine artery embolization had a 20% chance of undergoing hysterectomy in our 
cohort over 3.7 years of follow-up, similar to the hysterectomy rate in a large retrospective 
cohort study in the same local geographic area as our study [10]. The overall low rates of 
reoperation for all UPS highlight the effectiveness of UPS to avoid hysterectomy in most 
patients with symptomatic fibroids.
Medical management may also be an effective option for women with symptomatic fibroids, 
although there is limited evidence to support this approach. Studies of hormonal 
contraceptives to treat abnormal bleeding or pelvic pain have generally excluded women 
with fibroids. In our study, approximately half of the women who were using either 
combined contraceptives with estrogen and progestin or a progestin-only method reported 
that their symptoms improved “a lot” with these therapies. The progestin IUD was even 
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more effective, with 71% of users reporting that their symptoms became “a lot better”. This 
strong effect is consistent with prior studies that have reported a decrease in menstrual 
bleeding and pain in women with fibroids who utilize the progestin IUD [22].
The use of CAM to treat symptoms associated with fibroids is a unique finding in our study. 
Nearly 50% of women in the United States use CAM, with almost $19 billion in sales in 
2002 [24,25]. Prior studies have focused on the use of CAM to treat dysmenorrhea, 
infertility, and pregnancy-related nausea [26,27]. To our knowledge, however, CAM use to 
specifically address “pelvic problems” among women with symptomatic fibroids has not 
been previously reported. In our study, 40% of women were using exercise to treat their 
pelvic problems, 30% used specific foods or herbs to manage symptoms, and 15% used 
acupuncture. The effectiveness of CAM to improve pelvic symptoms was only moderate 
(36-43%), but bothersome side effects were extremely rare. The mechanism of how CAM 
may improve fibroid-related symptoms has not been elucidated, but some foods, vitamins 
and minerals have been found to decrease endometrial production of prostaglandins that are 
associated with vasoconstriction and myometrial contractions [27].
There are several limitations to our study. The diagnosis of fibroids is by self-report without 
specification of size, location, or the number of tumors. A prospective cohort study reported 
93% accuracy in the diagnosis of fibroids by self-report [28]. However, based on self-report, 
we were unable to confirm that a patient's fibroids were the primary cause of her pelvic 
symptoms. In addition, we could not determine specific fibroid characteristics that may have 
influenced satisfaction with medical management or symptom improvement among women 
who did not undergo surgery: selection bias may impact these results if, for instance, women 
with smaller fibroids were managed preferentially with these modalities. The reporting of 
surgery may have some inaccuracies without verification of the medical record. Finally, our 
results may not be generalizable to other patient populations, given the lack of geographic 
diversity in our sample and the effect of local practice patterns on the rates of hysterectomy 
and UPS to treat fibroids.
In this longitudinal study of women with symptomatic fibroids, we have described the 
natural history of fibroid-related symptoms among women who do and do not undergo 
fibroid surgery and the rate of an initial surgical intervention. Our findings indicate that 
nonsurgical management may be a viable option for many women and that medical 
treatment, including CAM, may significantly improve symptoms. Further research on the 
effectiveness of western medication and CAM, as well as expectant management, is needed 
to better inform counseling for women who wish to avoid surgery.
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Fig. 1. Use of medical treatments for symptomatic fibroids among women who did not undergo 
surgery
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Fig. 2. Effectiveness of western treatments and bothersome side effects among women who did 
not undergo surgery
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Fig. 3. Effectiveness of complementary and alternative treatments and bothersome side effects 
among women who did not undergo surgery
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Table 2
Uterus-preserving surgeries and hysterectomy during study follow-up, stratified by 
surgical procedures received prior to enrollment
Procedure during study follow-up N (%) Mean years of follow-up
No prior UPS at baseline, N=719
No surgery 530 (74) 3.7
Myomectomy 49 (7) 4.8
Uterine artery embolization 22 (3) 5.1
Endometrial ablation 8 (1) 4.2
Hysterectomy 110 (15) 5.0
Prior myomectomy, N=159
No surgery 104 (65) 3.8
Myomectomy 17 (10) 6.0
Uterine artery embolization 5 (3) 3.9
Endometrial ablation 2 (1) 8.0
Hysterectomy 31 (19) 5.8
Prior uterine artery embolization, N=29
No surgery 23 (79) 3.3
Myomectomy 0
Endometrial ablation 0
Hysterectomy 6 (20) 3.7
Prior endometrial ablation N=59
No surgery 47 (80) 3.0
Myomectomy 2 (3) 8.0
UAE 1 (2) 3.2
Hysterectomy 9 (15) 6.2
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Table 3
Changes in symptoms among women with no prior fibroid surgery: no surgery versus 
uterus-preserving surgery during study follow-up*
No surgery during 
study follow-up
Mean change from 
baseline to end of 
study (SE)
Uterus-preserving 
surgery during study 
follow-up
Mean change from 
baseline to end of 
study (SE)
Difference in 
change score 
(SE)
P value for 
difference in 
change score*
Pelvic problems resolved 0.43 (.06)† 1.62 (.17) † 1.18 (.18) <.001
Menstruation‡
Duration of menses (days) 0.18 (.31) -0.64 (.83) -.82 (.89) .35
Duration of heavy flow/passing clots (days) 0.0 (.21) -.88 (.56) -.88 (.46) .14
Spotting or bleeding between periods (days) -.37 (.33) -.77 (.88) -.39 (.77) .68
In the past 4 weeks, how bothered were 
you by….
Dyspareunia (painful sex)
-1.31 (.09) † -1.7 (.25) † -.39 (0.27) .14
Pelvic pain at other times
.19 (.08) † .04 (.22) -.15 (.23) .52
Tightness or pelvic pressure -0.09 (.08) -.0.04 (.22) 0.04 (.23) .85
Bladder pain
-.56 (.08) † -1.24 (.21) † -.67 (.22) .003
Frequent urination
.56 (.08) † -.27 (.20) -.83 (.24) <.001
Low back pain .08 (.09) -.40 (.26) -.48 (.27) .07
Menstrual cramps
-39 (.09) † -.39 (.12) .01 (.27) .98
*
Multivariable model controlled for age, ethnicity, education, cohort 1/cohort 2, length of follow-up, entry into menopause
†p<.001 for the change from baseline to the end of the study within each group
‡
These questions exclude women who entered menopause during the study period (N=268, 232 in no surgery group and 36 in UPS group).
Eur J Obstet Gynecol Reprod Biol. Author manuscript; available in PMC 2015 November 02.
